CG at a glance
Carlyle Group reported 19 positions worth $10.0 billion in its 13F-HR for Q2 2026, filed August 7, 2026. Its largest holdings were Medline Inc (MDLN) at 73.8%, Standardaero Inc (SARO) at 25.3% and Phathom Pharmaceuticals Inc (PHAT) at 0.4%.
- Versus Q1 2026, it opened 3 new positions, added to 2, trimmed 1 and sold out of 4. Reported portfolio value went from $10.6 billion to $10.0 billion.
- The 10 largest positions made up 99.9% of the reported portfolio.
- Largest estimated buys in Q2 2026: SunPower Inc (added, about $1.3 million), Riley Exploration Permian In (REPX) (new position, about $530,000) and Nebius Group N.V. (NBIS) (new position, about $510,000).
- For the fiscal year ended December 31, 2025 (FY2025), Carlyle Group (CG) reported revenue of $4.8 billion (down 11.9% from FY2024) and net income of $808.7 million. Diluted EPS was $2.18.
- As of June 30, 2026, 36 institutional investment managers tracked by SignalX reported holding Carlyle Group (CG) shares worth $4.2 billion in 13F-HR filings.
- The most recent insider open-market sale reported on Form 4 was by Rubenstein David M. on September 11, 2026 of 400,000 shares at $42.74 per share.
- In the last 90 days, CG insiders reported 0 open-market purchases ($0) and 1 open-market sale ($17.1M) on Form 4, a net sale of $17.1M.
Source: 13F-HR filings on SEC EDGAR.
- 13F portfolio · Q2 2026
- $10.0B
- −5.8% vs prior quarter
- Positions
- 19
- 3 new · 4 sold out
- Top 10 weight
- 99.9%
- Concentration of the 13F book
- Turnover
- 0%
- Quarter-over-quarter
- Revenue · FY2025
- $4.8B
- −11.9% vs prior year
- 13F holders
- 36 funds
- $4.2B · +2 vs prior quarter
- Latest 8-K
- Aug 5, 2026
- Item 2.02
Carlyle Group top 13F holdings, Q2 2026
Largest reported positions by market value, from the 13F-HR filed Aug 7, 2026
| # | Company | Weight | Value | Shares | vs Q1 2026 |
|---|---|---|---|---|---|
| 1 | Medline IncMDLN | 73.78% | $7.4B | 187,083,713 | Held |
| 2 | Standardaero IncSARO | 25.30% | $2.5B | 84,587,035 | Held |
| 3 | Phathom Pharmaceuticals IncPHAT | 0.38% | $37.9M | 3,496,808 | Held |
| 4 | Invitation Homes IncINVH | 0.20% | $20.0M | 662,900 | Held |
| 5 | Pony Ai IncPONY | 0.16% | $16.4M | 2,362,447 | Held |
| 6 | Getty Images Holdings IncGETY | 0.05% | $5.4M | 6,234,252 | Held |
| 7 | Spruce Biosciences Inc | 0.02% | $2.1M | 38,620 | Held |
| 8 | SunPower Inc | 0.02% | $1.6M | 2,343,750 | Added |
| 9 | Adicet Bio IncACET | 0.02% | $1.6M | 184,295 | Held |
| 10 | Forward Air Corp | 0.01% | $1.4M | 107,214 | Held |
| 11 | Onkure Therapeutics Inc | 0.01% | $1.2M | 269,895 | Held |
| 12 | Krispy Kreme IncDNUT | 0.01% | $1.2M | 340,748 | Held |
| 13 | Q32 Bio Inc | 0.01% | $769K | 60,363 | Trimmed |
| 14 | Riley Exploration Permian InREPX | 0.01% | $530K | 16,092 | New |
| 15 | Nebius Group N.V.NBIS | 0.01% | $510K | 1,846 | New |
| 16 | Robinhood Mkts IncHOOD | 0.01% | $475K | 4,733 | Added |
| 17 | Jasper Therapeutics Inc | 0.00% | $449K | 1,066,189 | Held |
| 18 | N-able IncNABL | 0.00% | $344K | 93,732 | Held |
| 19 | Ramaco Res IncMETC | 0.00% | $288K | 21,743 | New |
Source: Carlyle Group 13F-HR on SEC EDGAR. Long equity positions only (put and call options excluded); weights are shares of the reported 13F portfolio, not total assets. How 13F filings work
Carlyle Group biggest buys and sells, Q2 2026
Largest estimated position changes versus Q1 2026
| Company | Move | Est. flow | Shares now | Weight now |
|---|---|---|---|---|
| Q32 Bio Inc | Trimmed | −$13.3M | 60,363 | 0.01% |
| CubeSmartCTO | Sold out | −$8.1M | 0 | - |
| SunPower Inc | Added | +$1.3M | 2,343,750 | 0.02% |
| Riley Exploration Permian InREPX | New | +$530K | 16,092 | 0.01% |
| Nebius Group N.V.NBIS | New | +$510K | 1,846 | 0.01% |
| Heartflow IncHTFL | Sold out | −$497K | 0 | - |
| Spyre Therapeutics IncSYRE | Sold out | −$485K | 0 | - |
| Ramaco Res IncMETC | New | +$288K | 21,743 | 0.00% |
| Exicure Inc | Sold out | −$240K | 0 | - |
| Robinhood Mkts IncHOOD | Added | +$136K | 4,733 | 0.01% |
Estimated flow = change in share count × quarter-end price (3 new, 2 added, 1 trimmed, 4 sold out). 13F reports show holdings on the last day of the quarter, not the trade dates.
AI 10-Q Quarterly Report Analysis
Latest 10-Q, quarter ended Jun 30, 2026
Management Discussion & Analysis
- Liabilities $21.0B at June 30, down $1.1B from December 31, 2025
- Cash and equivalents $1.3B excluding Consolidated Funds
- Six-month share repurchases 7.9M shares, reducing outstanding shares to 353.4M
- Unfunded Carlyle fund commitments $4.3B, with $3.4B subscribed by professionals
- Contingent Abingworth payments up to $130.0M, with $16.1M accrued at June 30, 2026
Risk Factors
- Share-repurchase authorization reset to $2.0 billion effective February 26, 2026
- $1,630.9 million repurchase authorization remained as of June 30, 2026
- 6.6 million shares repurchased during the quarter at disclosed average prices of $46.97 and $44.64
AI summary of the CG 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K
AI 8-K Current Report Analysis
The most recent material events, by 8-K item
Item 2.02: Results of Operations and Financial Condition
- Q2 2026 results for quarter ended June 30, 2026, released August 5, 2026
- Detailed financial information available in Exhibits 99.1 and 99.2
Item 5.02: Departure/Appointment of Directors or Principal Officers
- Carlyle held its 2026 Annual Meeting on June 3, 2026
- Item 5.02 indicates officer or compensatory-arrangement disclosures, but the provided excerpt is incomplete
Item 5.07: Submission of Matters to a Vote of Security Holders
- All 13 director nominees elected for one-year terms, with FOR votes ranging from 287.6M to 300.0M
- Ernst & Young ratified as independent auditor for 2026, receiving 325.3M FOR votes versus 7.4M AGAINST
Item 5.02: Departure/Appointment of Directors or Principal Officers
- Jeffrey W. Ferguson retiring as General Counsel in 2026 after previously announcing departure plans
- Kate Heinzelman appointed General Counsel effective June 29, 2026
Item 7.01: Regulation FD Disclosure
- Exhibit 99.1 contains Carlyle’s press release and the substantive Regulation FD disclosure
- Investor relevance depends on the information provided in the referenced press release
AI summaries of CG 8-K current reports filed with the SEC. What 8-K item codes mean
SignalX for CG
Don't miss the next CG filing
- 13F alerts. A push when CG files a new 13F or a 13D stake.
- Smart Money consensus. Which stocks CG and other tracked funds bought together.
- Ask anything. An AI agent that reads every CG filing and answers with sources.
CG alerts on your phone. Follow it in the SignalX Android app.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| Rubenstein David M. | G | Sep 11, 2026 | 100,000 | - |
| Rubenstein David M. | Sell | Sep 11, 2026 | 400,000 | $42.74 |
| LoBue Lindsay | A | Aug 26, 2026 | 2,657 | - |
| SCHWARTZ HARVEY M | A | Aug 26, 2026 | 19,240 | - |
| Nedelman Jeffrey | A | Aug 26, 2026 | 6,615 | - |
| Heinzelman Kate Elizabeth | A | Aug 26, 2026 | 78 | - |
| Redett John C. | A | Aug 26, 2026 | 8,302 | - |
| Jenkins Mark David | A | Aug 26, 2026 | 6,264 | - |
Financial SummaryXBRL
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Profitability | |||
| Revenue | $3.0B | $5.4B | $4.8B |
| Net Income | -$608.4M | $1.0B | $808.7M |
| Net Margin | -20.5% | 18.8% | 16.9% |
| Balance Sheet | |||
| Total Assets | $21.2B | $23.1B | $29.1B |
| Equity | - | $6.3B | $7.1B |
| ROE | - | 16.1% | 11.5% |
| Per Share | |||
| EPS | $-1.68 | $2.77 | $2.18 |
| Cash Flow | |||
| Operating CF | $204.9M | -$759.5M | -$3.3B |
| CapEx | $66.6M | $77.7M | $99.4M |
Source: XBRL data in Carlyle Group (CG)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →
13F Fund Holdings: Quarterly Trend
Latest: Q2 2026Aggregate CG share value held by 13F filers tracked by SignalX, by quarter.
Quarterly totals table
| Quarter | Funds | Total value |
|---|---|---|
| Q2 2026 | 36 | $4.17B |
| Q1 2026 | 34 | $4.97B |
| Q4 2025 | 31 | $6.31B |
| Q3 2025 | 31 | $6.57B |
| Q2 2025 | 31 | $4.98B |
| Q1 2025 | 26 | $3.08B |
| Q4 2024 | 27 | $2.50B |
| Q3 2024 | 21 | $847.7M |
- BlackRock+959.6K (+3%)
- FMR LLC (Fidelity)+653.9K (+18%)
- Renaissance Technologies LLC+608.0K (+445%)
- Bank of America Corp+547.7K (+41%)
- D.E. Shaw & Co+221.4K (+1263%)
- Millennium Management−6.62M (-97%)
- Ameriprise Financial−694.8K (-26%)
- Morgan Stanley−179.0K (-2%)
- Franklin Resources−124.4K (-90%)
- JPMorgan Chase & Co−105.0K (-9%)
- Citadel Advisors LLC+835.2K
- Two Sigma Investments+48.9K
Source: 13F-HR filings on SEC EDGAR (aggregated from 237 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work
CG filing archive
AI analysis pages for each 10-K, 10-Q and 8-K
10-K annual reports
10-Q quarterly reports
8-K current reports
Latest Carlyle Group SEC filings
| Form | Filing date | Period | Analysis | SEC |
|---|---|---|---|---|
| 4 | Sep 11, 2026 | - | - | - |
| 4 | Aug 28, 2026 | - | - | - |
| 4 | Aug 28, 2026 | - | - | - |
| 4 | Aug 28, 2026 | - | - | - |
| 4 | Aug 28, 2026 | - | - | - |
| 4 | Aug 28, 2026 | - | - | - |
| 4 | Aug 28, 2026 | - | - | - |
| 4 | Aug 28, 2026 | - | - | - |
| 4 | Aug 28, 2026 | - | - | - |
| 10-Q | Aug 10, 2026 | Jun 30, 2026 | Analysis | |
| 13F-HR | Aug 7, 2026 | Jun 30, 2026 | - | |
| 8-K | Aug 5, 2026 | - | Analysis | - |
| 4 | Aug 4, 2026 | - | - | - |
| 4 | Aug 4, 2026 | - | - | - |
| 4 | Aug 4, 2026 | - | - | - |
| 4 | Aug 4, 2026 | - | - | - |
| 4 | Aug 4, 2026 | - | - | - |
| 4 | Aug 4, 2026 | - | - | - |
| 4 | Aug 4, 2026 | - | - | - |
| 8-K | Jun 5, 2026 | - | Analysis | |
| 8-K | Jun 1, 2026 | - | Analysis | |
| 4 | May 29, 2026 | - | - | |
| 4 | May 29, 2026 | - | - | |
| 4 | May 29, 2026 | - | - | |
| 4 | May 29, 2026 | - | - |
Related Financials companies
- ABX · Abacus Global Management, Inc.Investment Advice
- AAMI · Acadian Asset Management Inc.Investment Advice
- AMG · Affiliated Managers Group IncInvestment Advice
- ALTI · AlTi Global, Inc.Investment Advice
- AMP · Ameriprise FinancialInvestment Advice
- APO · Apollo Global ManagementInvestment Advice
- ARES · Ares ManagementInvestment Advice
- APAM · Artisan Partners Asset Management Inc.Investment Advice
CG 13F holdings: frequently asked questions
What stocks does Carlyle Group own?
In its 13F-HR for Q2 2026 (filed August 7, 2026), Carlyle Group reported 19 positions worth $10.0 billion. The largest were Medline Inc (MDLN), 73.8%; Standardaero Inc (SARO), 25.3%; Phathom Pharmaceuticals Inc (PHAT), 0.4%; Invitation Homes Inc (INVH), 0.2%; Pony Ai Inc (PONY), 0.2%. The top 10 positions were 99.9% of the portfolio.
What did Carlyle Group buy in Q2 2026?
Compared with Q1 2026, Carlyle Group's largest estimated purchases were SunPower Inc (added, about $1.3 million), Riley Exploration Permian In (REPX) (new position, about $530,000), Nebius Group N.V. (NBIS) (new position, about $510,000), Ramaco Res Inc (METC) (new position, about $288,000) and Robinhood Mkts Inc (HOOD) (added, about $136,000). In total it opened 3 new positions and added to 2. Amounts are estimated from share-count changes at quarter-end prices.
What did Carlyle Group sell in Q2 2026?
Compared with Q1 2026, Carlyle Group's largest estimated sales were Q32 Bio Inc (trimmed, about $13.3 million), CubeSmart (CTO) (sold out, about $8.1 million), Heartflow Inc (HTFL) (sold out, about $497,000), Spyre Therapeutics Inc (SYRE) (sold out, about $485,000) and Exicure Inc (sold out, about $240,000). In total it sold out of 4 positions and trimmed 1.
When does Carlyle Group file 13F reports?
Carlyle Group's latest 13F-HR was filed August 7, 2026 and covers the quarter ended June 30, 2026. 13F-HR reports are due within 45 days of each quarter-end, so the Q3 2026 report is due by November 14, 2026.
Are CG insiders buying or selling?
In the last 90 days, Carlyle Group (CG) officers, directors and 10% owners reported no open-market purchases and 1 open-market sale worth $17.1 million by 1 insider on Form 4. Many insider sales are pre-planned or for taxes, so purchases usually carry more information.
Which institutions hold CG stock?
As of June 30, 2026, the largest Carlyle Group (CG) holders among the 13F filers tracked by SignalX were BlackRock ($1.3 billion), Vanguard Portfolio Management LLC ($498.2 million), Vanguard Capital Management LLC ($482.8 million), Morgan Stanley ($420.8 million), State Street Corp ($416.6 million). 13F-HR reports are filed up to 45 days after each quarter ends.
What was CG's revenue in fiscal year 2025?
For the fiscal year ended December 31, 2025 (FY2025), Carlyle Group (CG) reported revenue of $4.8 billion (down 11.9% from FY2024) and net income of $808.7 million. Diluted EPS was $2.18. The figures come from the XBRL data in the 10-K.
What did CG report in its latest 8-K?
Carlyle Group (CG) filed an 8-K on August 5, 2026 reporting Item 2.02 (Results of Operations and Financial Condition). Q2 2026 results for quarter ended June 30, 2026, released August 5, 2026.
What are the latest CG SEC filings?
Carlyle Group (CG) filed its latest 10-K annual report on February 27, 2026, a 10-Q quarterly report on August 10, 2026, an 8-K current report on August 5, 2026 and a Form 4 insider filing on September 11, 2026.
What is CG's SEC CIK number?
Carlyle Group (CG)'s SEC Central Index Key (CIK) is 1527166. EDGAR lists every CG filing under that number.
Ask anything about CG
The research agent reads CG's filings, financials, insider trades and 13F holders, then answers with sources.